Jan 09, 2023 / 04:15PM GMT
Christopher Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott at JP Morgan, and it's my pleasure to be introducing Royalty Pharma to this morning at the JP Morgan Healthcare Conference. We think this is a really unique business and a company that's very much helping fund some of the innovation that's occurring across the biopharma industry.
From the company, we have Pablo Legorreta, the company's founder and CEO, and then we're going to go to the Q&A afterwards with a broader swath of the management team. So Pablo, Happy New Year. Thanks for joining us and look forward to the presentation.
Pablo Legorreta - Royalty Pharma plc - Founder, Chairman of the Board & CEO
Chris, thank you very much, and it's such a pleasure to be here today. My first time as a presenter. I've been coming to the conference for 26 years, but Royalty Pharma was private for a long time, and thanks to the help of Chris and the JP Morgan team, we took it public in June of 2020.
So I'm Pablo Legorreta,
Royalty Pharma PLC at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot